The nation of Zimbabwe has declined a major US healthcare agreement worth $367m (£272m) over five years because of the United States' demand for confidential data.
This move came to light after a official document dated December was leaked, which showed Head of State Emmerson Mnangagwa believed the agreement was "skewed".
A government spokesman has since clarified that the United States was requesting biological samples for research and profit but was not willing to share the resulting advantages from any future treatments.
"We must now begin the difficult and regrettable process of ending our health aid in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the United States had provided over $1.9bn as health assistance to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has called for further dialogue to find a agreement suitable to both sides so the nation's critical HIV programme can be sustained.
Broader Implications
This rejection comes after a similar case in neighbouring Kenya, where a court suspended a related health funding agreement following legal challenges were filed about the safety of citizens' health data.
Since returning to the presidency recently, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
The agency had overseen assistance for the US government, but Trump stated its expenditure was "inefficient" and his government was pursuing direct bilateral deals to boost openness and accountability.
Based on reports, 16 African countries have so far agreed to similar agreements, representing more than $18.3bn in committed funds.
Details of the Declined Agreement
The funds for Zimbabwe would have funded "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this partnership might have yielded extraordinary benefits for the people of Zimbabwe, especially the 1.2 million presently on HIV treatment via US-supported initiatives," the Ambassador added.
However, official spokesman Nick Mangwana maintained the proposed deal was "unfair".
"Zimbabwe was being asked to share its genetic material and health information for a long time, without any corresponding promise of access to any medical innovations – like vaccines, diagnostics, or treatments – that might result from that shared data," Mangwana explained.
"Effectively, our country would provide the basic resources for scientific discovery with no certainty that the final treatments would be available to our citizens should a new disease outbreak arise."
National Interest and Global Health
He also pointed out that the American exit from the global health body and its pursuit of bilateral deals were undermining systems previously set up through the international health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing system designed to manage potential pandemics.
"This mechanism is intended to ensure that when a nation contributes its information, the benefits – including medicines and cures – are shared equitably, not monopolised solely by those with the capability to develop them."
Zimbabwe's reservations regarding the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We welcome ongoing dialogue with our US partners on how subsequent collaboration might be designed in a way that honours the independence and interests of each country."
Health Experts Reaction
A leading public health body expressed it recognised the official position, but urged that negotiations should continue considering much of the nation's HIV programmes were funded by external financing.
"In cases where technical issues exist, including those relating to data governance or implementation frameworks, these can often be addressed through technical clarification and mutually agreed protections," it commented.
This impasse emphasises the continuing tensions between accepting vital international aid and protecting a country's data in an increasingly data-driven world.